Nivolumab plus Ipilimumab in Advanced Melanoma

Abstract

Concurrent therapy with nivolumab and ipilimumab had a manageable safety profile and provided clinical activity that appears to be distinct from that in published data on monotherapy, with rapid and deep tumor regression in a substantial proportion of patients. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; ClinicalTrials.gov number, NCT01024231.).

Keywords

IpilimumabMedicineNivolumabRegimenAdverse effectInternal medicineMelanomaOncologyCancerImmunotherapyCancer research

Affiliated Institutions

Related Publications

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Robert J. Motzer , Nizar M. Tannir , Ray McDermott +29 more

Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate- and poor-risk patients with previo...

2018 New England Journal of Medicine 4403 citations

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Suzanne L. Topalian , F. Stephen Hodi , Julie R. Brahmer +27 more

Anti-PD-1 antibody produced objective responses in approximately one in four to one in five patients with non-small-cell lung cancer, melanoma, or renal-cell cancer; the adverse...

2012 New England Journal of Medicine 12335 citations

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

F. Stephen Hodi , Steven O’Day , David F. McDermott +26 more

Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma. Adverse eve...

2010 New England Journal of Medicine 14794 citations

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

James Larkin , Vanna Chiarion‐Sileni , René González +28 more

BACKGROUND Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advance...

2019 New England Journal of Medicine 3500 citations

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Caroline Robert , Jacob Schachter , Georgina V. Long +19 more

The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced mela...

2015 New England Journal of Medicine 5661 citations

Publication Info

Year: 2013
Type: article
Volume: 369
Issue: 2
Pages: 122-133
Citations: 4169
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Nivolumab plus Ipilimumab in Advanced Melanoma

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

4169

OpenAlex

Cite This

APA Style

                            
                                
                                    Jedd D. Wolchok, 
                                
                                    Harriet M. Kluger, 
                                
                                    Margaret K. Callahan
                                
                                et al.
                            
                            (2013). 
                            Nivolumab plus Ipilimumab in Advanced Melanoma. 
                            New England Journal of Medicine
                            , 369
                            (2)
                            , 122-133.
                            https://doi.org/10.1056/nejmoa1302369
                        

Identifiers

DOI: 10.1056/nejmoa1302369